Novo Nordisk to Halve Ozempic and Wegovy Prices in the U.S. Starting 2027
Novo Nordisk has announced it will reduce the list prices of its popular diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50% in the United States. The new pricing will take effect in January 2027.
After the reduction, both medications will have a list price of $675 per month. Novo Nordisk aims to make these treatments more affordable, especially for people with insurance plans that base out-of-pocket expenses on the list price. This includes individuals with high-deductible health plans or those with co-insurance arrangements.
The company stated that lowering the list prices is meant to help more people access their innovative medicines.
Novo Nordisk wants to make these drugs more affordable for people whose out-of-pocket costs are tied to the list price, such as those with high-deductible or co-insurance health plans.
The lower prices for Ozempic and Wegovy will start in January 2027.
Both drugs will have a list price of $675 per month after the reduction.
WSJ
Forbes
CNBC
Fox Business
New York Post
24/7 Wall Street
Benzinga